Current Appointments & Affiliations
Medical Assistant Professor in the Department of Medicine
·
2025 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2023 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Journal Article Cancer Res Commun · June 1, 2025 PURPOSE: Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) portends a poor prognosis. DNA pathway repair mutations in HNSCC are associated with higher tumor mutational burden rates and immune checkpoint inhibitor response. PARP inhibit ... Full text Link to item CiteComparative analysis of the tumor microbiome, molecular profiles, and immune cell abundances by HPV status in mucosal head and neck cancers and their impact on survival.
Journal Article Cancer Biol Ther · December 31, 2024 Head and Neck Squamous Cell Carcinoma (HNSCC) comprises a diverse group of tumors with variable treatment response and prognosis. The tumor microenvironment (TME), which includes microbiome and immune cells, can impact outcomes. Here, we sought to relate t ... Full text Link to item CiteAssociation between Tumor Microbiome and Hypoxia across Anatomic Subsites of Head and Neck Cancers.
Journal Article Int J Mol Sci · December 8, 2022 Purpose/Objective(s): Microbiome has been shown to affect tumorigenesis by promoting inflammation. However, the association between the upper aerodigestive microbiome and head and neck squamous cell carcinoma (HNSCC) is not well established. Hypoxia is a m ... Full text Link to item CiteRecent Grants
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMABAND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA
Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2025 - 2030Phase 3 open-label, randomized, controlled study to evaluate the efficacy & safety of petosemtamab compared with investigators choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell
Clinical TrialPrincipal Investigator · Awarded by Merus N.V. · 2025 - 2030A phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Clinical TrialPrincipal Investigator · Awarded by Merus N.V. · 2025 - 2030View All Grants
Education, Training & Certifications
Sri Venkateswara University (India) ·
2011
M.D.